Loading...
•
Sep 30, 2021
Treace Q3 2021 Earnings Report
Reported a 52% increase in revenue compared to the same period last year, launched Adductoplasty™ System, and treated the first patient in the Mini3D™ clinical study.
Key Takeaways
Treace Medical Concepts reported a revenue of $21.6 million for Q3 2021, a 52% increase compared to Q3 2020. The company launched the Adductoplasty™ System and treated the first patient in the Mini3D™ clinical study. They are reaffirming revenue guidance to be in the range of $90 million to $95 million for the full year 2021.
Revenue of $21.6 million, a 52% increase over the same period last year and a 4.7% increase sequentially
Gross margin of 80.4%, an increase of 80 basis points from the same period last year
Commercial launch of AdductoplastyTM System
First patient treated in Mini3D™ Lapiplasty® clinical study
Forward Guidance
Treace is reaffirming revenue guidance to be in the range of $90 million to $95 million for the full year 2021, which represents approximately 57% to 65% growth over the Company’s 2020 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...